Navigation Links
BioMotiv Secures $46 Million in Funding
Date:8/5/2013

CLEVELAND, Aug. 5, 2013 /PRNewswire-USNewswire/ -- BioMotiv, a drug development accelerator based in Cleveland, Ohio, today announced that it has increased its total capital from investors to $46 million, adding Nationwide Mutual Insurance Company and several individual investors to its founding investors, University Hospitals of Cleveland and the Harrington Family.  Nationwide Mutual Insurance Company also will appoint a representative to serve on the Board of Managers of BioMotiv. 

(Logo: http://photos.prnewswire.com/prnh/20130805/DC57374LOGO)

"BioMotiv is a new business model for accelerating breakthrough discoveries into medicines, aligning capital and collaborations to develop a portfolio of therapeutics," said Baiju R. Shah, Chief Executive Officer of BioMotiv.  "This support from local institutions and investors provides the company a strong foundation on which to build nationally."

Launched last year, BioMotiv has established its organization and operations and attracted a world-renowned advisory board that includes several former heads of global pharmaceutical research and development organizations to manage a portfolio of promising drug technologies.  The company is affiliated with The Harrington Project for Discovery and Development, a $250 million national initiative initiated by University Hospitals.

"We license early-stage technologies and then develop them with the oversight of our experienced team and network of partners," said Shah.  BioMotiv has begun work on several promising technologies sourced from research institutions and industry sources.

BioMotiv continues to seek additional early-stage therapeutic technologies that are at the pre-clinical or early-clinical stage of development. 

About The Harrington Project

The Harrington Project for Discovery and Development is a $250 million national initiative to support the discovery and development of breakthrough discoveries by physician-scientists.  The Harrington Project, centered at University Hospitals Case Medical Center, is a new and powerful national model that addresses a set of challenges in advancing medicine through its innovative approach.  It includes the Harrington Discovery Institute and BioMotiv. The project, powered by a generous gift and investment from the Harrington family, successful entrepreneurs and recognized philanthropists in Cleveland, provides a comprehensive model to advance discoveries into development and to create novel therapies for patient care.

For more information about the Harrington Discovery Institute, go to: www.uhharringtondiscoveryinstitute.org.

For more information about BioMotiv, go to: www.BioMotiv.com.


'/>"/>
SOURCE BioMotiv
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMotiv Secures $21 million in Initial Funding
2. BioMotiv Names New Chief Executive Officer
3. Stark Medical Secures GSA Schedule Contract, Looks to Supply VA
4. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
5. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
6. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
7. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
8. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
9. United Spinal Secures Victory in Protecting Access to Complex Rehab Technology in Washington State
10. Alimera Sciences Secures $20 Million Debt Facility
11. Henry Schein Secures $300 Million Of Committed Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor ... global anti-obesity drugs market is expected to grow at a ... and CAGR of 38.7% in the second half of the forecast ... 32.8% from 2016 to 2027. The market is estimated at $1,058 ... 2027. ...
(Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
(Date:1/19/2017)... 2017 ViewRay, Inc. (Nasdaq: VRAY) announced today that ... research in Germany , has purchased ... the University Clinic Heidelberg as part of its initiative ... program will be headed by Medical Director and Professor ... at the German Cancer Research Center (DKFZ), the Heidelberg ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out of ... show to continue the marketing and distribution of its product, The Right C. , ... percent better absorption than traditional vitamin C supplements. At the trade show, Doctor C ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company ... bodybuilding supplements, announced it attended the January ECRM trade show in Hilton Head, SC. ... scientist who was determined to create a line of products that would elevate her ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More ... to the issue of world hunger, and shares the simple and achievable answer. “The ... husband and member of the Fairview Missionary Church in Angola, Indiana where he works ...
Breaking Medicine News(10 mins):